← Back to headlines
Atea Pharmaceuticals Stock Drops Despite Positive Hepatitis C Trial Results
Atea Pharmaceuticals' stock experienced a decline despite the company announcing a successful late-stage trial for its hepatitis C therapy.
28 Jul, 15:50 — 28 Jul, 15:50
Sources
Showing 1 of 1 sources
